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Objectives: This study has been performed to observe the efficacy & safety of Topiramate in refractory epilepsies 
in children in Pakistan. 
Materials and Methods: A cross-sectional prospective consecutive series of children age between (1-14 years) 
with refractory epilepsy were recruited from the Paediatric Neurology clinic of Izzat Ali Shah Hospital. Epilepsy 
was classified into Generalized, Focal, and Unknown based on ILAE Classification. Topiramate was added in 
patients who were refractory to at least two anti-epileptic drugs. The outcome was recorded in four categories i.e 
total remission, >50% seizure reduction, <50% seizure reduction, and no improvement. 
Results: Fifty-eight patients were enrolled in the study, but 5 patients were dropped out due to significant side 
effects. Most of the children were in the age group ranging from 5 to 10 years with predominant boys (n=32). The 
major type of epilepsy was 53% (n=28) was Unknown, while 36% (n=19) children had Generalized epilepsy and 
11% (n=6) had Focal epilepsy. 25% children had total remission, 38% had >50% seizure reduction, 28% had < 50% 
seizure reduction and 9% had no improvement. Total remission was mostly seen in Focal epilepsy (50%) and least 
shown in Unknown type (14%) and the difference was significant (Chi-Square test p=0.039). Adverse effects to 
Topiramate were found in 33 (62%) of the total enrolled patients. Common adverse effects were weight loss in 
14(26%), poor appetite in 13(24.5%), and behavioral issues in 6(22.5%) children. 
Conclusion: Topiramate is an effective anti-epileptic drug (AED) in refractory epilepsy especially with Focal and 
Generalized onset but is not as effective in other types of Refractory epilepsy. Weight loss and poor appetite were 
the commonest adverse effects that were reversible after dose reduction.  
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Introduction 
 
Topiramate is mainly an anti-epileptic drug (AED) 
which is a carbonic anhydrase inhibitor. Topiramate is 
a 2,3:4,5-di-O-isopropylidene-β-d-
fructopyranose sulfamate compound.1 It acts by 
blocking sodium channels, enhancing GABA-induced 
influx of chloride, and inhibiting kinate/AMPA 
glutamate receptors.2-3 Topiramate is well absorbed 
orally. It is not extensively metabolized & is eliminated 
unchanged in the urine. Hence, it indicates that 
urinary excretion is a major route of excretion. Chronic 
renal and hepatic impairment can affect the clearance 
of Topiramate.4 
It is clinically used for a different type of epilepsy but 
has an important role in infantile spasms and Lennox-
Gastaut syndrome. It is also used in the prevention of 
Migraines, Bipolar disorder, Schizophrenia, Bulimia 
nervosa, binge eating disorders, alcohol dependence, 
weight loss, mood instability disorder, obesity, etc.5-7 
Spritzer et al analyzed the literature and concluded 
that Topiramate is also effective in patients having 
both Epilepsy and Migraine.8 Topiramate can be given 
alone or in combination with other drugs in 
Generalized Tonic-Clonic seizures or Focal seizures.9 
Topiramate can have drug interactions with 
Phenytoin, Valproic acid, and Carbamazepine. Some 
patients attain higher Phenytoin serum levels when 
Topiramate is added to their drug regime. On the 
other hand serum Topiramate levels may be reduced 
when given with Phenytoin and Carbamazepine. 
Marques et al monitored the plasma concentration 
level of Topiramate in patients with epilepsy and 
found it below the therapeutic range in 83% of 
patients. Antiepileptic drug inducers tend to reduce 
their plasma concentration, hence increases the risk of 
seizures.10 
Refractory Epilepsy is uncontrollable, intractable, or 
drug-resistant epilepsy, which is the failure of 
adequate trials of at least two tolerated and 
appropriately chosen anti-epilepsy drugs (AEDs) to 
achieve sustained seizure freedom for a sufficiently 
long period of time.11 The incidence of refractory 
epilepsy in developed countries is 6 per 1000 patients 
of epilepsy but it ranges from 7% to 35% and a greater 
range is more applied to children.12 There is no data 
available regarding its incidence in the Pakistani 
population. The cause of refractory epilepsy is often 
not known. There are very few studies reported 
regarding the efficacy of Topiramate in refractory 
epileptic children.  Kanner et al reviewed 13 years of 
literature for refractory epilepsy treatment and 
suggested treatment guidelines in adults and children. 
Topiramate was mainly recommended in Focal 
epilepsy.13 Asadi-pooya et al described a 
comprehensive review of Lennox-Gastaut Syndrome 
(LGS) and considered Topiramate as the first-line 
treatment for LGS along with Valporate and 
Lamotrigine.14 Gomes et al proposed the treatment 
protocol for the super-refractory status epilepticus and 
suggested Topiramate with other anti-epileptics along 
with anesthetic medicines.15 
This study was designed to assess the effectiveness of 
Topiramate in children with refractory epilepsy in 
Pakistan as no previous studies are reported in this 
region. 
 
Materials and Methods 
 
The primary objective was to observe the efficiency & 
safety of Topiramate in refractory epilepsies in 
children in Pakistan. 
Study Design and settings:  A cross-sectional 
prospective consecutive series of children age between 
(1-14 years) with refractory epilepsy were identified 
from January 2019 to December 2020. The children 
were recruited from the Paediatric Neurology clinic of 
Izzat Ali Shah Hospital. 
Patients were selected according to the following 
criteria: (i) age between 1–14 years. (ii) Refractory 
epilepsy (iii) currently on two or more AEDs. 
Electroencephalograph (EEG) & Computerized 
Tomography (CT) or MRI Brain was performed in all 
patients. Epilepsy was classified into three categories 
according to ILAE 2017 Operational Classification. (i) 
Generalized Epilepsy (ii) Focal Epilepsy and (iii) 
Unknown. 
Verbal consent was obtained from the caregivers. 
Topiramate was started at the daily dose of 1 mg/kg 
followed by 2 weekly increments up to a maximum 
daily dose of 10 mg/kg at all ages. If a child was not 
able to tolerate, developed fever or extreme lethargy 
after starting the Topiramate then he/she was 
excluded from the study, and Topiramate was 
stopped. With minor side effects listed in Table 2, the 
study was continued. Parents or caregivers were asked 
to record the change in seizure duration and 
frequency. All the children were followed up for a 
mean period of 3-6 months. Responses were recorded 
according to the following four categories. (i) 
Complete remission (ii) >50% seizure reduction (iii) 
<50% seizure reduction (iv) No improvement. All the 
results were recorded in predesigned proforma. 
Patients were asked to attend the hospital anytime if 
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any side effect occurred. Side effects were also 
recorded during follow-up visits. The collected data 




Fifty-eight children were enrolled in the study. Five 
patients were dropped out from the study due to 
significant side effects. Their demographic 
characteristics are mentioned in Table 1. Most of the 
children (n=27) enrolled had an age range between 5 
to 10 years with predominantly boys (n=32). The major 
type of epilepsy 53% (n=28) was Unknown, while 36% 
(n=19) children had Generalized epilepsy and 11% 
(n=6) had Focal epilepsy. Most of the children (87%) 
were receiving more than two AEDs.  
The response of Topiramate is given in Table 2 where 
25% of children had total remission, 38% had >50% 
seizure reduction, 28% had < 50% seizure reduction 
and 9% had no improvement yet there was no case 
with a worse response. Total remission was mostly 
seen in Focal epilepsy (50%) and least shown in 
Unknown types (14%). More than 50% seizure 
reduction was seen in all types of epilepsy. Less than 
50% improvement was mostly seen in unknown types. 
In children with Generalized refractory epilepsy, there 
was a satisfactory response (total remission plus >50% 
seizure reduction) to Topiramate in 15 of our 19 cases. 
In children with Focal epilepsy, there was a 
satisfactory response to Topiramate in 5 out of 6 cases. 
According to the correlation between types of 
epilepsies and their responses, the difference is 
significant (Chi-Square test p=0.039). Table 3 shows the 
clinical response to Topiramate according to age 
categories. Ages between 1 to 10 years showed better 
response than age between 11 to 14 years but it was 
not statistically significant (p=0.216). 
Adverse effects to Topiramate are mentioned in Table 
4 and were found in 33 (62%) of the total enrolled 
patients. Some of adverse effects were seen in children 
like somnolence in 2 (3.5%), poor appetite in 
13(24.5%), behavioral issues in 6(22.5%), fatigue in 
1(2%), fever in 5(9%), psychomotor slowing in 1(2%), 
weight loss 14(26%), sleep disturbances in 4(7.5%) & 
others in 2(3.5%). 
 
Table 1: Demographic & baseline characteristics of 





Age Range (years)   
1 to 5 29 54% 
6 to 10  17 32% 
11 to 14 7 13% 
Gender   
Boys  32 60.5% 
Girls 21 39.5% 
Epilepsy classification    
Generalized  19 36% 
Focal  6 11% 
Unknown 28 53% 
Number of background 
AEDs 
  
Two AED 7 13% 
More than 2 AEDs 46 87% 
 
Table 2: Responses to Topiramate according to the clinical types of epilepsy  










Generalized (n=19) 6 (32%) 9 (47%) 3 (16%) 1 (5%) 0.039 
 Focal (n=6) 3 (50%) 2 (33%)  1 (17%) 
Unknown (n=28) 4 (14 %) 9 (32%) 12 (43%) 3 (11%) 
Total (n=53) 13(25%) 20(38%) 15(28%) 5(9%) 
 
Table 3: Response to Topiramate according to age categories 








1-5 years (n=29) 7(24%) 12(41%) 8(28%) 2(7%) 0.216 
6-10 years (n=17) 4(23%) 8(48%) 5(29) 0 
11-14 years (n=7) 2(29%) 0 2(29%) 3(42%) 
Total (n=53) 13(24%) 20(38%) 15(28%) 5(1%) 
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Table 4: Side effects observed during treatment with 
Topiramate (n=33) 





Somnolence 2 3.5% 
Poor appetite  13 24.5% 
Behavioral issues  6 11% 
Fatigue  1 2% 
Abdominal pain - - 
Headache  - - 
Fever 5 9% 
Psychomotor slowing 1 2% 
Dizziness  -  
Weight loss 14 26% 
Visual complain -  
Memory complain -  
Sleep disturbance 4 7.5% 




This study shows that Topiramate is effective and 
well-tolerated in infants and children with Refractory 
epilepsy. The response was more satisfactory in a focal 
and generalized type of epilepsy as compared to the 
unknown category.  
In a quite similar study, Al Ajlouni et al reported that 
60% of children with Refractory epilepsy showed a 
satisfactory response (total and more than 50% 
remission) while the remaining 40% showed an 
unsatisfactory response.16 Hassan et al reported that 
34% of children with uncontrollable seizures became 
seizure-free and 39% achieved more than 50% 
reduction in seizure frequency.17 Ritter et al reported 
>50% reduction in symptom frequency in 57% of 
children with Partial epilepsy, and 14% became 
seizure-free.18 Coppola et al achieved seizure-free 
status in 20% of children with Refractory Partial 
epilepsy and 45% of patients had a 50% reduction in 
seizure frequency.19 Biton et al achieved >50% 
reduction in their seizure frequency in 46% of children 
with primary generalized epilepsy compared to the 
17% in the placebo control group.20  Glauser et al 
concluded that 15% of children with Lennox Gastaut 
syndrome showed total improvement while 55% had 
more than 50% reduction in seizure frequency.21 Kato 
et al compared the efficacy and tolerability of 
Topiramate, Lamotrigine, and Levetiracetam in 
children with Refractory epilepsy. A total of 55 
children received Topiramate, 44 children had 
Lamotrigine, and 38 received Levetiracetam. He 
concluded that Levetiracetam was the most effective 
drug in Refractory childhood epilepsy with partial and 
Generalized epilepsy, while Topiramate was effective 
in Partial epilepsy and Lamotrigine in Generalized 
epilepsy.22 Unalp et al concluded that 51 children 
(72%) showed a good response to initial treatment but 
a loss of efficacy in long-term use occurred in 17 
(33.3%) of initial responders.23 Liu et al studied that 
Topiramate is effective both as monotherapy and add 
on therapy in post-operative neurosurgical patients.24 
It is also recommended that in younger children 
dosage may be adjusted according to response rather 
than using the absolute Topiramate dose. It is, 
therefore, possible that higher doses (>10mg/kg/day) 
may prove to be more effective in the future.25 As 
shown in Table 3, most of the side effects of 
Topiramate were minor and the drug was well 
tolerated. Side effects were noted in 62% of patients, 
the most common side effects in our study were loss of 
appetite, weight loss, and behavioral issues and the 
least common was psychomotor slowing which was 
noticed in only one child in our study. As compared to 
other studies we experienced fewer cognitive side 
effects. Some of our patients also complained of fever 
which resolved spontaneously. Most of the side effects 
were transient which resolved spontaneously or with 
dose reduction. In Al Ajlouni's study, the most 
common side effects were Somnolence, Poor appetite, 
and Irritability.16 Coppola et al suggested Topiramate 
as the first choice in the treatment of generalized 
epilepsy but highlighted the side effects related to 
cognition and memory.26 Our study didn't record any 




In this study, it is concluded that Topiramate is an 
effective AED in Refractory epilepsy especially with 
Focal and Generalized onset but it is not as effective in 
other types of Refractory epilepsy. Weight loss and 
poor appetite were the commonest adverse effects that 
were reversible after dose reduction. Topiramate is a 
worthy option for children with high seizure 
frequency refractory to standard AEDs. 
This study did not compare Topiramate with other 
drugs in refractory epilepsy and it is recommended 
that further comparative studies may be conducted to 
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